GlassScriptPhysician profile
Richard S Field
NPI 1689632093
$19,495.18
in general payments reported to CMS, 2019-2025
37 companies · $3,560 in 2025
The $3,560 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,232 · 2020: $1,567 · 2021: $2,196 · 2022: $2,772 · 2023: $3,338 · 2024: $3,831 · 2025: $3,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,728.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,306.91 | 2019-2025 | |
| Amgen INC. | $2,637.07 | 2019-2025 | Tavneos, Enbrel, Krystexxa |
| Ucb, INC. | $1,953.86 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,543.17 | 2019-2025 | |
| Janssen Biotech, INC. | $1,320.20 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,141.16 | 2019-2025 | |
| Glaxosmithkline, LLC. | $874.44 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $491.11 | 2019-2025 | Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $416.80 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $349.48 | 2019-2023 | Orencia |
| Mallinckrodt Hospital Products INC. | $240.92 | 2023-2025 | Acthar |
| Genentech USA, INC. | $207.02 | 2021-2025 | Actemra, Gazyva |
| Radius Health, INC. | $204.26 | 2019-2025 | Tymlos |
| Organon LLC | $203.20 | 2023-2025 | Renflexis, Hadlima |
| Fresenius Kabi USA, LLC | $176.24 | 2023-2025 | Tyenne, Idacio |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.11 | 2020-2024 | |
| Genzyme Corporation | $166.49 | 2019-2020 | |
| Horizon Therapeutics Plc | $120.57 | 2019-2023 | Krystexxa |
| Octapharma USA, INC. | $112.95 | 2022-2024 | Octagam Immune Globulin (Human), Panzyga |
| Sobi, INC | $107.09 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $86.87 | 2023-2025 | Tremfya |
| Scilex Pharmaceuticals INC. | $80.70 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $75.43 | 2021-2024 | Opsumit |
| Mylan Institutional INC. | $65.60 | 2023 | Hulio |
| Aurinia Pharma U.S., INC. | $62.37 | 2025 | Lupkynis |
| Kiniksa Pharmaceuticals, LTD. | $62.05 | 2022-2023 | Arcalyst |
| Tersera Therapeutics LLC | $50.37 | 2021-2024 | Quzyttir |
| Medexus Pharma, INC. | $48.50 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $45.72 | 2023 | Purified Cortrophin Gel |
| Celgene Corporation | $39.85 | 2019-2024 | Orencia |
| Merck Sharp & Dohme LLC | $26.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.71 | 2025 | Cuvitru |
| Boston Scientific Corporation | $20.65 | 2025 | Wavewriter Alpha Prime 16 |
| Kiniksa Pharmaceuticals International, Plc | $20.17 | 2024 | Arcalyst |
| Almatica Pharma LLC | $15.23 | 2025 | Teriparatide |
| Teva Pharmaceuticals USA, INC. | $14.39 | 2023 | Truxima |
| Alexion Pharmaceuticals, INC. | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Field listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.